COLO.B.DK

566

-0.81%↓

GMAB.DK

2,086

+2.51%↑

HLUNB.DK

45.28

-0.09%↓

ZEAL.DK

505.2

-0.75%↓

AMBUB.DK

106.2

+2.21%↑

COLO.B.DK

566

-0.81%↓

GMAB.DK

2,086

+2.51%↑

HLUNB.DK

45.28

-0.09%↓

ZEAL.DK

505.2

-0.75%↓

AMBUB.DK

106.2

+2.21%↑

COLO.B.DK

566

-0.81%↓

GMAB.DK

2,086

+2.51%↑

HLUNB.DK

45.28

-0.09%↓

ZEAL.DK

505.2

-0.75%↓

AMBUB.DK

106.2

+2.21%↑

COLO.B.DK

566

-0.81%↓

GMAB.DK

2,086

+2.51%↑

HLUNB.DK

45.28

-0.09%↓

ZEAL.DK

505.2

-0.75%↓

AMBUB.DK

106.2

+2.21%↑

COLO.B.DK

566

-0.81%↓

GMAB.DK

2,086

+2.51%↑

HLUNB.DK

45.28

-0.09%↓

ZEAL.DK

505.2

-0.75%↓

AMBUB.DK

106.2

+2.21%↑

Search

Novo Nordisk A-S (Class B)

Ouvert

373.4 0.04

Résumé

Variation du prix de l'action

24h

Actuel

Min

366.1

Max

375.55

Chiffres clés

By Trading Economics

Revenu

-2.5B

27B

Ventes

-1.2B

77B

P/E

Moyenne du Secteur

13.758

35.739

BPA

5.96

Rendement du dividende

3.31

Marge bénéficiaire

34.484

Employés

78,387

EBITDA

44B

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+9.53% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.31%

3.08%

Prochains Résultats

5 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

141B

1.5T

Ouverture précédente

373.36

Clôture précédente

373.4

Novo Nordisk A-S (Class B) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

1 oct. 2025, 08:54 UTC

Principaux Mouvements du Marché

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

18 août 2025, 13:52 UTC

Principaux Mouvements du Marché

GoodRx Partners With Novo Nordisk to Lower Cost of Weight-Loss Drugs

18 août 2025, 09:23 UTC

Principaux Mouvements du Marché

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

18 août 2025, 09:23 UTC

Principaux Mouvements du Marché

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

6 août 2025, 06:52 UTC

Résultats

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues -- Update

6 août 2025, 06:21 UTC

Résultats

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues

1 oct. 2025, 09:05 UTC

Actions en Tendance

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

29 sept. 2025, 12:04 UTC

Market Talk

Novo Nordisk Faces Headwind as U.S Obesity Drugs Stall, Competition Rises -- Market Talk

22 sept. 2025, 13:43 UTC

Acquisitions, Fusions, Rachats

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

18 sept. 2025, 12:30 UTC

Market Talk

Correction to Novo Nordisk Market Talk

18 sept. 2025, 12:00 UTC

Market Talk

Novo Nordisk's Prospects Could Turn Around -- Market Talk

18 sept. 2025, 08:55 UTC

Actions en Tendance

Stocks to Watch Thursday: Nvidia, PayPal, Novo Nordisk -- WSJ

11 sept. 2025, 10:59 UTC

Market Talk

Novo Nordisk Investors Cheer Plans to Slim Organization -- Market Talk

10 sept. 2025, 13:24 UTC

Résultats

Ozempic Maker Novo Nordisk to Cut 9,000 Jobs -- Update

10 sept. 2025, 09:16 UTC

Actions en Tendance

Stocks to Watch Wednesday: Oracle, GameStop, Novo Nordisk -- WSJ

2 sept. 2025, 09:14 UTC

Actions en Tendance

Stocks to Watch Tuesday: Nestlé, Novo Nordisk, Nvidia -- WSJ

21 août 2025, 08:49 UTC

Résultats
Actions en Tendance

Stocks to Watch Thursday: Meta, Coty, Walmart, Novo Nordisk -- WSJ

18 août 2025, 09:23 UTC

Actions en Tendance

Stocks to Watch Monday: Novo Nordisk, Soho House, UnitedHealth -- WSJ

8 août 2025, 05:32 UTC

Market Talk

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

7 août 2025, 11:32 UTC

Résultats

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 août 2025, 11:03 UTC

Résultats

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 août 2025, 10:41 UTC

Résultats

Eli Lilly Stock Drops on Weight-Loss Pill Data Ahead of Earnings -- Barrons.com

6 août 2025, 20:34 UTC

Résultats

Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday -- Barrons.com

6 août 2025, 08:45 UTC

Résultats

Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress. -- Barrons.com

6 août 2025, 07:19 UTC

Market Talk
Résultats

Novo Nordisk Sales in Line, Boosted by One-Off Rebate -- Market Talk

6 août 2025, 05:50 UTC

Résultats

Novo Nordisk: Gudiance Assumes Macroeconomic, Political Environment Won't Significantly Change Business Conditions During 2025

6 août 2025, 05:48 UTC

Résultats

Novo Nordisk Declares Interim Dividend of DKK3.75 Vs DKK3.50

6 août 2025, 05:46 UTC

Résultats

Novo Nordisk Will Continue to Invest in Expanding Direct-to-Patient Initiatives For Wegovy

6 août 2025, 05:38 UTC

Résultats

Novo Nordisk 2Q Ozempic Drug Sales DKK31.8B Vs DKK28.88B

6 août 2025, 05:37 UTC

Résultats

Novo Nordisk 2Q Wegovy Drug Sales DKK19.53B Vs DKK11.66B

Comparaison

Variation de prix

Novo Nordisk A-S (Class B) prévision

Objectif de Prix

By TipRanks

9.53% hausse

Prévisions sur 12 Mois

Moyen 1,162.73 DKK  9.53%

Haut 1,550 DKK

Bas 720 DKK

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

11 ratings

7

Achat

2

Maintien

2

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
help-icon Live chat